🔎 Trials Near Me

ホーム › 血液がん › カリフォルニア州

カリフォルニア州における血液がんの臨床試験

カリフォルニア州内の拠点で、血液がんに関する35件の研究が参加者を募集しています。

カリフォルニア州内の都市

公式研究テキスト(英語)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

  • Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054), Bakersfield
  • UCLA - Hematology/Oncology - Administrative Office ( Site 0009), Los Angeles
  • Stanford Cancer Center ( Site 0086), Palo Alto
  • 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03486873

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
  • PCR Oncology, Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
  • 他20件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

  • University of California San Diego Moores Cancer Center ( Site 2717), La Jolla
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT04728893

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 1, Duarte
  • Quetzal Site 7, Los Angeles
  • Quetzal Site 5, Stanford
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345

Wearable Activity Tracking to Curb Hospitalizations

  • University of California, San Francisco, San Francisco
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/23更新 · NCT06587100

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

  • PCR Oncology, Arroyo Grande
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
  • Washington Health, Fremont
  • 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/09/17更新 · NCT04242095

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCLA Medical Center, Los Angeles
  • Stanford Cancer Institute, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • City of Hope Medical Center, Duarte
  • University of California San Diego Medical Center, Moores Cancer Center, La Jolla
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916

M-2018-334 in Hematological Malignancies

  • City of Hope, Duarte
被験者募集中
18歳〜75歳 · 全性別 · 2026/09/11更新 · NCT06225050

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope National Medical Center, Duarte
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

  • City of Hope Medical Center, Duarte
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/08/28更新 · NCT07186192

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of California, Fresno, Clovis
  • University of California, San Diego, La Jolla
  • Cedars-Sinai Medical Center, Los Angeles
  • 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • USC Norris Comprehensive Cancer Center, Los Angeles
  • UCLA Health - Bowyer Oncology Center, Los Angeles
  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
  • 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

  • City Of Hope, Duarte
  • University of California, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06823167

Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

  • Cedars-Sinai Medical Center, Los Angeles
被験者募集中第1相
65歳以上 · 全性別 · 2026/08/05更新 · NCT05849207

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

  • City of Hope National Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT06665100

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

  • START Los Angele, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • UCLA Department of Medicine, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • City of Hope, Duarte
  • Children's Hospital of Los Angeles, Glendale
  • Scripps Green Hospital, La Jolla
  • 他8件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

IVIG for Infection Prevention After CAR-T-Cell Therapy

  • City of Hope Cancer Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05952804

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

  • University of California LA, Los Angeles
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/11更新 · NCT06401356

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

  • UC San Diego Moores Cancer Center, La Jolla
  • University of California, San Francisco, San Francisco
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/01更新 · NCT05663502

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • UCSF Medical Center-Mission Bay, San Francisco
被験者募集中第3相
2歳〜18歳 · 全性別 · 2026/05/05更新 · NCT05711667

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • City of Hope, Duarte
  • Providence St. John's Health Center, Santa Monica
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

  • USC / Norris Comprehensive Cancer Center, Los Angeles
被験者募集中観察研究健康なボランティア歓迎
19歳以上 · 全性別 · 2026/04/02更新 · NCT03207854

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Moores UC San Diego Cancer Center, La Jolla
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • UCLA - Bowyer Oncology Center, Los Angeles
  • 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

  • Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/02/02更新 · NCT06028828

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

  • University of Southern California - Norris Comprehensive Cancer Center, Los Angeles
被験者募集中観察研究
18歳以上 · 全性別 · 2025/06/25更新 · NCT05768269

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • Valkyrie Clinical Trials, Los Angeles
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/03更新 · NCT06119685

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

  • City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/15更新 · NCT06462365

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital Orange County, Orange
  • UCSF School of Medicine, San Francisco
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。